Document is current
Any future updates will be listed below
-
Authors
Schüller, Simone S.
Barman, Soumik https://orcid.org/0000-0002-3641-2125
Mendez-Giraldez, Raul https://orcid.org/0000-0003-1853-9429
Soni, Dheeraj https://orcid.org/0000-0002-5555-2051
Daley, John
Baden, Lindsey R.
Levy, Ofer https://orcid.org/0000-0002-5859-1945
Dowling, David J. https://orcid.org/0000-0003-1095-6156
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00044, 272201800047C, 272201800047C-P00003-9999))
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 22 September 2023
Accepted: 27 May 2024
First Online: 8 June 2024
Competing interests
: The authors declare the following competing financial interest(s): D.S., O.L. and D.J.D. are named inventors on patents relating to small molecule adjuvants assigned to Boston Children’s Hospital. O.L.’s laboratory has received sponsored research support from <i>GlaxoSmithKline</i> (GSK) and O.L. has served as a consultant to GSK and <i>Hillevax</i>. D.J.D. is on the scientific advisory board of <i>EdJen BioTech</i> and serves as a consultant with Merck Research Laboratories/Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.). O.L. and D.J.D. are cofounders of <i>Ovax Inc</i>. These commercial or financial relationships are unrelated to the current study. R.M.G. is an Application Fields Scientist for the Cytobank platform at Beckman Coulter Life Sciences. The rest of the authors declare no competing interests.
